Ultra Health, one of New Mexico’s medical cannabis providers, released pharmaceutical-grade, smokeless products to the state’s market earlier this week.

The products were developed with proprietary knowledge from Israeli pharmaceutical group Panaxia, Ultra Health’s press release states, and include rectal and vaginal suppositories, sublingual tablets, tablets, topicals, oils and patches.

Ultra Health claims the products provide previously unavailable delivery methods for medical cannabis patients, including those suffering from PTSD, Parkinson’s disease, chronic pain, and epilepsy among others. Dosages range from 10 to 200 milligrams of THC and 5 to 300 milligrams of CBD.

The sublingual tablet is useful for patients who have difficulty swallowing because the blood vessels in the cheek area allow medication to be absorbed directly into the blood stream without going through the digestive system. Rectal and vaginal suppositories are also useful for these patients, as the fast-acting medication is absorbed directly into the bloodstream after being inserted with a special applicator.